Peru will market products at the CBD in pharmacies “for various indications prescribed by a doctor,” opening the door to trade in hemp-derived medicines.
Two products are registered as “natural health products derived from cannabis” in Peru. The first is Epifractan, manufactured in Uruguay by Ramm Pharma, which contains 5% CBD for -0.2% THC and will be distributed by the Peruvian company CannaFarm. The second is Sativex from GW Pharmaceuticals, which is prescribed for multiple sclerosis and contains a 1:1 ratio of THC and CBD.
Peru legalized medical cannabis in 2017 and has one of the most advanced regulations for cannabis in Latin America.
Companies with registered products must obtain the necessary import permits to receive their products and distribute them to pharmacies in the country.
After obtaining the import permit, we expect to receive the first shipment from Uruguay and begin supplying Peruvian patients in the coming weeks, said Andres Vazquez Vargas, President of CannaFarm.
Epifractan has been available in Uruguayan pharmacies by prescription since 2018 and also distributed in other countries in the region, such as Brazil and Argentina, as part of compassionate use cannabis programs. Ramm Pharma ships on a case-by-case basis to patients who have a named authorization.
As of 10 July, the public database of the Peruvian health authority indicated that 17 registrations for cannabis-based medicines had submitted by six companies and were awaiting approval.